MicroRNA-21與肺動脈高壓的相關(guān)性研究
發(fā)布時間：2019-04-23 11:30
【摘要】：目的:通過比較microRNA-21(miRNA-21,miR-21)表達(dá)水平與心導(dǎo)管檢查術(shù)所測得的臨床上常用的肺動脈壓力及肺血管阻力指標(biāo)水平的相關(guān)性,探討miRNA-21與肺動脈高壓(pulmonary arterial hypertension,PAH)之間的關(guān)系及彼此的相關(guān)性,明確miRNA-21在PAH嚴(yán)重程度評估中的應(yīng)用價值。從而為今后PAH的診斷工作指引一個新的思路。方法:收集2016年11月-2017年03月期間于廣西區(qū)人民醫(yī)院心內(nèi)科住院的患者,所有行心導(dǎo)管檢查,并經(jīng)導(dǎo)管完整行多點測量壓力及抽血行血氣分析者61例。其中男性20例,女性41例。參照ESC于2015年公布的最新的肺動脈高壓診斷指南:患者靜息狀態(tài),心導(dǎo)管檢查術(shù)測定的平均肺動脈壓力(mPAP)≥25 mmHg進行分組,分為肺動脈壓力PAP增高組17例(A組)和肺動脈壓力PAP正常組44例(B組)。入院后第二天早晨,留取入組患者肘靜脈血液5ml送至廣西區(qū)人民醫(yī)院科研實驗中心運用Trizol法提取總RNA,反轉(zhuǎn)錄得到cDNA,進行實時熒光定量PCR檢測,再根據(jù)2-△△CT法計算出miRNA-21的相對表達(dá)量。收取患者住院期間所有臨床基線資料。運用SPSS 20.0軟件分析數(shù)據(jù),分析miRNA-21在肺動脈高壓病變的篩查、嚴(yán)重程度的診斷、預(yù)后評價以及治療后隨訪的評估中的臨床應(yīng)用價值。結(jié)果:(1)A、B兩組平均肺動脈壓力mPAP分別為(41.24±13.06)mmHg、(19.90±2.41)mmHg,差異存在統(tǒng)計學(xué)意義(P0.05);肺血管阻力PVR分別為(4.97±0.91)Wood、(3.40±0.54)Wood,差異存在統(tǒng)計學(xué)意義(P0.05);肺血管阻力指數(shù)PVRi分別為(7.74±1.18)、(5.28±1.03),差異存在統(tǒng)計學(xué)意義(P0.05);肺體循環(huán)血流量比值Qp/Qs分別為(1.58±0.42)、(1.31±0.21),差異存在統(tǒng)計學(xué)意義(P0.05)。(2)A、B兩組miRNA-21相對表達(dá)量分別為(5.26±1.06)、(3.69±0.86),差異存在統(tǒng)計學(xué)意義(P0.05)。(3)A、B兩組患者miRNA-21的表達(dá)量與平均肺動脈壓力mPAP之間的相關(guān)系數(shù)為r=0.631(P0.05),且呈線性相關(guān)(F=38.947,P0.05);miRNA-21的表達(dá)量與肺血管阻力PVR之間的相關(guān)系數(shù)為r=0.522(P0.05),且呈線性相關(guān)(F=22.123,P0.05);miRNA-21表達(dá)水平與肺血管阻力指數(shù)PVRi之間呈中等程度相關(guān)(r=0.503,P0.05),且呈線性相關(guān)(F=20.020,P0.05);miRNA-21表達(dá)水平與肺體循環(huán)血流量比值Qp/Qs之間呈無明顯相關(guān)性(P=0.165)。結(jié)論:肺動脈高壓患者miRNA-21的表達(dá)水平明顯升高,miRNA-21可作為肺動脈高壓病變評估及預(yù)后評價的指標(biāo);
[Abstract]:Objective: to investigate the relationship between the expression of microRNA-21 (miRNA-21,miR-21) and pulmonary arterial pressure and pulmonary vascular resistance (PVR) measured by cardiac catheterization in order to explore the relationship between miRNA-21 and pulmonary hypertension (pulmonary arterial hypertension,). The relationship and correlation between PAH) were used to determine the value of miRNA-21 in PAH severity assessment. So as to guide a new train of thought for the diagnosis of PAH in the future. Methods: 61 patients who were hospitalized in the Department of Cardiology of Guangxi people's Hospital from November 2016 to March 2017 were collected. All patients underwent cardiac catheterization, and 61 patients underwent multipoint pressure measurement and blood gas analysis. There were 20 males and 41 females. According to the latest ESC guidelines for the diagnosis of pulmonary hypertension published in 2015: patients' resting status, the mean pulmonary arterial pressure measured by cardiac catheterization was grouped into groups with a mean pulmonary artery pressure of more than 25 mmHg. They were divided into two groups: group A (17 cases) with increased pulmonary arterial pressure (PAP) and 44 cases (group B) with normal pulmonary arterial pressure (PAP). In the morning after admission, the blood 5ml from the elbow vein of the patients in the group was sent to the scientific research and experiment center of Guangxi people's Hospital by using Trizol method to extract the total RNA, reverse transcription to obtain cDNA, for real-time fluorescence quantitative PCR detection. Then the relative expression of miRNA-21 was calculated by 2-CT method. Receive all clinical baseline data during hospitalization. The clinical value of miRNA-21 in the diagnosis of pulmonary hypertension, the diagnosis of severity, the evaluation of prognosis and the evaluation of follow-up after treatment were analyzed by using SPSS 20.0 software to analyze the clinical application value of miRNA-21 in pulmonary hypertension disease screening, severity diagnosis and prognosis evaluation. Results: (1) the mean pulmonary artery pressure (mPAP) in group A and B was (41.24 鹵13.06) mmHg, () 19.90 鹵2.41 mmHg, (P0.05). Pulmonary vascular resistance (PVR) was (4.97 鹵0.91) Wood, () 3.40 鹵0.54 Wood, (P0.05). The pulmonary vascular resistance index (PVRi) was (7.74 鹵1.18), (5.28 鹵1.03), the difference was statistically significant (P0.05). The ratio of pulmonary systemic blood flow (Qp/Qs) was (1.58 鹵0.42), (1.31 鹵0.21), the difference was statistically significant (P0.05). (2) A, and the relative expression of miRNA-21 in group B was (5.26 鹵1.06), respectively. (3.69 鹵0.86), the difference was statistically significant (P0.05). (- 3) A, the correlation coefficient between the expression of miRNA-21 and the mean pulmonary artery pressure mPAP in group B was 0. 631 (P0.05), and there was a linear correlation between the expression and the mean pulmonary artery pressure (mPAP) (F = 38. 947, P < 0. 05). (P 0.05); The correlation coefficient between the expression of miRNA-21 and pulmonary vascular resistance (PVR) was r = 0.522 (P0.05), and there was a linear correlation (F = 22.123, P0.05). There was a moderate correlation between the expression of miRNA-21 and pulmonary vascular resistance index (PVRi) (r = 0.503, P 0.05), and a linear correlation (F = 20.020, P 0.05). There was no significant correlation between the expression of miRNA-21 and the ratio of pulmonary systemic blood flow (Qp/Qs) (P < 0. 165). Conclusion: the expression level of miRNA-21 in patients with pulmonary hypertension is significantly higher, and miRNA-21 can be used as a marker for evaluating the pathological changes of pulmonary hypertension and evaluating the prognosis.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R544.1
本文編號：2463424
[Abstract]:Objective: to investigate the relationship between the expression of microRNA-21 (miRNA-21,miR-21) and pulmonary arterial pressure and pulmonary vascular resistance (PVR) measured by cardiac catheterization in order to explore the relationship between miRNA-21 and pulmonary hypertension (pulmonary arterial hypertension,). The relationship and correlation between PAH) were used to determine the value of miRNA-21 in PAH severity assessment. So as to guide a new train of thought for the diagnosis of PAH in the future. Methods: 61 patients who were hospitalized in the Department of Cardiology of Guangxi people's Hospital from November 2016 to March 2017 were collected. All patients underwent cardiac catheterization, and 61 patients underwent multipoint pressure measurement and blood gas analysis. There were 20 males and 41 females. According to the latest ESC guidelines for the diagnosis of pulmonary hypertension published in 2015: patients' resting status, the mean pulmonary arterial pressure measured by cardiac catheterization was grouped into groups with a mean pulmonary artery pressure of more than 25 mmHg. They were divided into two groups: group A (17 cases) with increased pulmonary arterial pressure (PAP) and 44 cases (group B) with normal pulmonary arterial pressure (PAP). In the morning after admission, the blood 5ml from the elbow vein of the patients in the group was sent to the scientific research and experiment center of Guangxi people's Hospital by using Trizol method to extract the total RNA, reverse transcription to obtain cDNA, for real-time fluorescence quantitative PCR detection. Then the relative expression of miRNA-21 was calculated by 2-CT method. Receive all clinical baseline data during hospitalization. The clinical value of miRNA-21 in the diagnosis of pulmonary hypertension, the diagnosis of severity, the evaluation of prognosis and the evaluation of follow-up after treatment were analyzed by using SPSS 20.0 software to analyze the clinical application value of miRNA-21 in pulmonary hypertension disease screening, severity diagnosis and prognosis evaluation. Results: (1) the mean pulmonary artery pressure (mPAP) in group A and B was (41.24 鹵13.06) mmHg, () 19.90 鹵2.41 mmHg, (P0.05). Pulmonary vascular resistance (PVR) was (4.97 鹵0.91) Wood, () 3.40 鹵0.54 Wood, (P0.05). The pulmonary vascular resistance index (PVRi) was (7.74 鹵1.18), (5.28 鹵1.03), the difference was statistically significant (P0.05). The ratio of pulmonary systemic blood flow (Qp/Qs) was (1.58 鹵0.42), (1.31 鹵0.21), the difference was statistically significant (P0.05). (2) A, and the relative expression of miRNA-21 in group B was (5.26 鹵1.06), respectively. (3.69 鹵0.86), the difference was statistically significant (P0.05). (- 3) A, the correlation coefficient between the expression of miRNA-21 and the mean pulmonary artery pressure mPAP in group B was 0. 631 (P0.05), and there was a linear correlation between the expression and the mean pulmonary artery pressure (mPAP) (F = 38. 947, P < 0. 05). (P 0.05); The correlation coefficient between the expression of miRNA-21 and pulmonary vascular resistance (PVR) was r = 0.522 (P0.05), and there was a linear correlation (F = 22.123, P0.05). There was a moderate correlation between the expression of miRNA-21 and pulmonary vascular resistance index (PVRi) (r = 0.503, P 0.05), and a linear correlation (F = 20.020, P 0.05). There was no significant correlation between the expression of miRNA-21 and the ratio of pulmonary systemic blood flow (Qp/Qs) (P < 0. 165). Conclusion: the expression level of miRNA-21 in patients with pulmonary hypertension is significantly higher, and miRNA-21 can be used as a marker for evaluating the pathological changes of pulmonary hypertension and evaluating the prognosis.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R544.1
【參考文獻(xiàn)】
相關(guān)期刊論文 前2條
1 徐鳳;錢玲玲;王如興;;微小RNA在冠狀動脈性心臟病中的研究進展[J];中華醫(yī)學(xué)雜志;2013年26期
2 丁仲如;秦永文;;先天性心臟病合并肺動脈高壓分級及性質(zhì)的評估[J];介入放射學(xué)雜志;2008年07期
，本文編號：2463424
本文鏈接：http://sikaile.net/yixuelunwen/xxg/2463424.html
最近更新
教材專著
